Novo Nordisk: London FY 2012 Investor Presentation (Novo Nordisk) - Mar 5, 2013 - "NovoThirteen was effective in preventing bleeding after once-monthly dosing for 12 months; Annual frequency of bleeds requiring treatment was 0.138 (vs. 2.91 for historical controls); Treatment with NovoThirteen was generally safe with only transient, non-neutralising antibody formation being reported in few patients"
P3 data • Hemophilia
|